View Financial HealthDiagonal Bio 配当と自社株買い配当金 基準チェック /06Diagonal Bio配当金を支払った記録がありません。主要情報n/a配当利回り-275.9%バイバック利回り総株主利回り-275.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 22Diagonal Bio AB (Publ) Announces Change the Nomination CommitteeDiagonal Bio AB (publ) announced change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025. Based on the above, the Nomination Committee for the AGM 2025 has been changes to consist of the following persons; Anna Frick, represents Svea Bank AB, Chairman of the Committee, Juha Kauppinen, represents Daniel Redén Trotting AB, John Moll, represents WWAdvise AB/Karin Wehlin, Kerstin Jakobsson, Observer, Chairman Diagonal Bio AB.お知らせ • Mar 21Diagonal Bio AB (Publ) Receives Patent in Japan for it's Key Technology (`A DNA/RNA Detection Platform')Diagonal Bio AB (publ) announced that the Japanese Patent Office has confirmed the grant of a patent (application number: EP3987059B1) to Diagonal Bio for the Company's key technology ('A DNA/RNA detection platform'). At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia.お知らせ • Mar 06Nasdaq Approves Diagonal Bio's Application for Delisting from Nasdaq First North Growth MarketDiagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announced that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The last day of trading on First North is 18 March 2025 and the Company will instead be listed on NGM Nordic SME ("NGM") with a planned first day of trading on 19 March 2025, provided that no new information emerges that affects the listing. The granting of the delisting application is conditioned by Diagonal Bio fulfilling the formal listing requirements of NGM and thus, that the securities in Diagonal Bio are admitted to trading on NGM. Shareholders in Diagonal Bio will not need to take any action in connection with the change of marketplace.お知らせ • Jan 18Diagonal Bio AB (Publ) Announces Nomination Committee ChangesAccording to the instructions for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three larger shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next larger shareholder in terms of voting rights. Based on the above, the Nomination Committee for the AGM 2025 has been changes to consist of the following persons: Svante Olofsson, represents own shareholdings, Chairman of the Committee, Juha Kauppinen, represents own shareholdings, Lars Moberg, represents own shareholdings, Kerstin Jakobsson, Observer, Chairman Diagonal Bio AB and Ylber Rexhepi no longer qualifies.お知らせ • Nov 19Diagonal Bio AB (publ), Annual General Meeting, May 20, 2025Diagonal Bio AB (publ), Annual General Meeting, May 20, 2025.お知らせ • Nov 13Diagonal Bio AB (publ) Announces Pilot Test with LAMPlify at Kolgjini StablesDiagonal Bio AB (publ) announced a partnership with Kolgjini Stables (Stall Kolgjini, to conduct a three-month pilot test. Kolgjini Stables is a Swedish stable known for its expertise in growing horses for both breeding and for top-tier national and international competition. This pilot test starts immediately and aims to evaluate the potential of the LAMPlify® platform to provide rapid and accurate virus detection in horses. KolgjiniStables, led by Lutfi Kolgjini, is a prominent player both in harness racing and horse breeding. The facility, located near Lund holds up to 180 horses. The large number of horses in proximity makes rapid virus detection especially critical to prevent the spread of infections within the stables. A rapid diagnostic method allows breeders to promptly isolate infected horses, proactively safeguarding their animals' health and minimising the risk of transmission. The pilot test at Kolgjini Stables are part of Diagonal Bio's ongoing strategy to commercialise the LAMPlify®®? solution aimed at horse breeders seeking solutions to prevent the spreading of viruses. The result of this pilot test will help ensure that LAMPlify® effectively meets the specific needs of the horse breeding and racing industry.Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr1.24m (loss narrowed 53% from 3Q 2023).お知らせ • Nov 01+ 3 more updatesDiagonal Bio AB (publ) to Report Q3, 2025 Results on Oct 31, 2025Diagonal Bio AB (publ) announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Oct 25Diagonal Bio AB (publ) Announces Pilot Test of LAMPlify at Norwegian University of Life SciencesDiagonal Bio AB (publ) announced the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify, at the Norwegian University of Life Sciences (NMBU) in Ås. The pilot, which will be conducted in collaboration with the Faculty of Veterinary Medicine and Biosciences, specifically the Department of Companion Animal Clinical Sciences, aims to evaluate the effectiveness and potential integration of LAMPlify within the university's equine hospital. The veterinary team at NMBU, led by Associate Professor Ingunn Risnes Hellings, will test LAMPlify in their animal hospital laboratory. As a leading teaching and commercial hospital, the equine department treats horses from across Norway, and this pilot will explore the feasibility of adopting LAMPlify as a vital tool for rapid, on-site diagnostics in their medicine department. The pilot test will provide crucial insights into whether LAMPlify can meet the hospital's needs for efficient, point- of-care diagnostics, potentially transforming the way they manage and treat equine patients.お知らせ • Oct 12Diagonal Bio Announces Successful External Validation of LAMPlify for Viruses in PigusesDiagonal Bio AB (publ) announced successful results of a recent pilot study conducted by the Centre for Diagnostics at DTU Health Technology. The study evaluated the performance of the LAMPlify assay panel for tests specific to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) type 1 and type 2, and Swine Influenza Virus (SIV), by comparing it to the gold-standard PCR (qPCR) tests. The study showed excellent agreement between the LAMPlify®?assays and qPCR tests, yielding identical positive/negative classifications between the methods. The samples were selected by Centre for Diagnostics, DTU (Danmarks Tekniske Universitet), among the ones submitted for diagnostic examination at the Veterinary Institute. In total, four PRRSV1 positive, one PRRSV2 positive and eight SIV positive samples were included in this study.お知らせ • Oct 09Diagonal Bio AB (publ) Announces Hunneberga Horse Stable to Conduct Pilot Test of LAMPlifyDiagonal Bio AB announces that Hunneberga Horse Stable (Hunneberga Hästgård) and Tomas Hammar, showjumping trainer and CEO at Hunneberga Horse Stable, has initiated a partnership with Diagonal Bio to conduct a pilot test. The agreement is set to three months and will involve a testing program of LAMPlify to detect respiratory viral infections in showjumping horses during upcoming competitions. The pilot will start immediately. Tomas Hammar, responsible for 20 competition horses and actively participating in both national and international events, sees great value in continuously ensuring the health of those horses through regular testing. At competitions, where horses from different stables gather, there is always a risk that infectious diseases such as respiratory viruses, influenza, and herpes viruses (for example EHV1 and EHV4) are spread. These viruses can spread quickly and affect both the well-being of the horses and their ability to compete. This pilot test is intended to provide faster and more accurate point-of-care diagnostics, thereby enhancing health outcomes for showjumping horses and ensuring more secure horse competitions. The pilot, which will run for three months, will involve using LAMPlify® on Hunneberga Horse Stable's horses at every event, both to protect their own horses and to demonstrate the technology to other trainers and horse owners. The study also aims to showcase how LAMPlify can become a new standard for quick and easy testing within the equestrian sports.Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr3.44m (loss widened 23% from 2Q 2023).Reported Earnings • Jun 04First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr255.0k (down 75% from 1Q 2023). Net loss: kr2.99m (loss narrowed 19% from 1Q 2023).お知らせ • Jun 02+ 2 more updatesDiagonal Bio AB (publ) to Report Q2, 2024 Results on Aug 22, 2024Diagonal Bio AB (publ) announced that they will report Q2, 2024 results on Aug 22, 2024お知らせ • May 24Diagonal Bio AB (publ) Appoints Fata Mrsic as Chief Financial Officer, Effective June 14, 2024Diagonal Bio AB (publ) has appointed Fata Mrsic as the new Chief Financial Officer (CFO). Fata will assume the position on June 14, 2024, and be part of the Management Team. Fata Mrsic has extensive financial and accounting experience. She has held Business Controller and Accounting positions at several companies in the past 15 years, some with global presence. Fata has a Diploma in Business Controlling from the University of Lund.お知らせ • May 16Diagonal Bio AB (publ), Annual General Meeting, Jun 11, 2024Diagonal Bio AB (publ), Annual General Meeting, Jun 11, 2024, at 13:00 W. Europe Standard Time. Location: at medicon village, scheeletorget 1, lund Swedenお知らせ • Apr 05Diagonal Bio AB (Publ) Announces Successful Pilot Study ResultsDiagonal Bio AB (publ) announced the extension of its partnership with Horsholm Veterinary Clinic following the successful completion of a three-month pilot study. The pilot study was focused on utilizing Diagonal Bio's platform technology, LAMPlify®, for the detection of viral infections in horses. The successful results were validated by an independent external laboratory in Germany, underscoring the efficacy and reliability of the LAMPlify® analysis system. The pilot study tested Diagonal Bio's LAMPlify® technology on a series of samples from horses suspected of carrying respiratory viruses. The tests confirmed the presence of virus infections in several of the horses tested. The pilot study not only demonstrated LAMPlify®'s capability to accurately identify viral infections but also proved that it is a valuable tool in the early detection of such diseases, thereby enabling timely intervention and treatment.Reported Earnings • Mar 01Full year 2023 earnings released: kr0.34 loss per share (vs kr1.70 loss in FY 2022)Full year 2023 results: kr0.34 loss per share (improved from kr1.70 loss in FY 2022). Revenue: kr3.18m (down 14% from FY 2022). Net loss: kr11.7m (loss narrowed 28% from FY 2022).お知らせ • Feb 29Diagonal Bio Appoints Karin Wehlin as New CEODiagonal Bio AB (publ) announced that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin is currently Diagonal Bio’s interim CEO. Karin Wehlin was elected to the Board of Directors of Diagonal Bio in the spring of 2023, and on November 23, 2023, she was appointed as interim CEO. Karin holds an Executive MBA degree from Lund University and has completed education at INSEAD in Strategy, Innovation, and Leadership. She has over 25 years of experience in senior positions within the Life Science sector, and has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB. Karin has also worked as Manager in Corporate Finance and is the founder of EQL Pharma AB, where she served as the Executive Chairman of the board for 10 years.New Risk • Nov 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 12% over the past year. Shareholders have been substantially diluted in the past year (337% increase in shares outstanding). Revenue is less than US$1m (kr3.6m revenue, or US$327k). Market cap is less than US$10m (€1.31m market cap, or US$1.41m).Reported Earnings • Nov 06Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr789.0k (down 39% from 3Q 2022). Net loss: kr2.66m (loss narrowed 29% from 3Q 2022).Board Change • Aug 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 23Diagonal Bio AB (publ) announced that it expects to receive SEK 1.8 million in fundingDiagonal Bio AB announced a private placement to issue common shares for the gross proceeds of SEK 1,800,000 on August 22, 2023.Board Change • Jul 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 26Full year 2022 earnings released: kr1.77 loss per share (vs kr1.70 loss in FY 2021)Full year 2022 results: kr1.77 loss per share (further deteriorated from kr1.70 loss in FY 2021). Revenue: kr3.73m (down 57% from FY 2021). Net loss: kr16.2m (loss widened 39% from FY 2021).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 9F1の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 9F1の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Diagonal Bio 配当利回り対市場9F1 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (9F1)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Biotechs)2.4%アナリスト予想 (9F1) (最長3年)n/a注目すべき配当: 9F1は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 9F1は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 9F1の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 9F1が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/15 13:54終値2025/10/31 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Diagonal Bio AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 22Diagonal Bio AB (Publ) Announces Change the Nomination CommitteeDiagonal Bio AB (publ) announced change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025. Based on the above, the Nomination Committee for the AGM 2025 has been changes to consist of the following persons; Anna Frick, represents Svea Bank AB, Chairman of the Committee, Juha Kauppinen, represents Daniel Redén Trotting AB, John Moll, represents WWAdvise AB/Karin Wehlin, Kerstin Jakobsson, Observer, Chairman Diagonal Bio AB.
お知らせ • Mar 21Diagonal Bio AB (Publ) Receives Patent in Japan for it's Key Technology (`A DNA/RNA Detection Platform')Diagonal Bio AB (publ) announced that the Japanese Patent Office has confirmed the grant of a patent (application number: EP3987059B1) to Diagonal Bio for the Company's key technology ('A DNA/RNA detection platform'). At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia.
お知らせ • Mar 06Nasdaq Approves Diagonal Bio's Application for Delisting from Nasdaq First North Growth MarketDiagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announced that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The last day of trading on First North is 18 March 2025 and the Company will instead be listed on NGM Nordic SME ("NGM") with a planned first day of trading on 19 March 2025, provided that no new information emerges that affects the listing. The granting of the delisting application is conditioned by Diagonal Bio fulfilling the formal listing requirements of NGM and thus, that the securities in Diagonal Bio are admitted to trading on NGM. Shareholders in Diagonal Bio will not need to take any action in connection with the change of marketplace.
お知らせ • Jan 18Diagonal Bio AB (Publ) Announces Nomination Committee ChangesAccording to the instructions for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three larger shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next larger shareholder in terms of voting rights. Based on the above, the Nomination Committee for the AGM 2025 has been changes to consist of the following persons: Svante Olofsson, represents own shareholdings, Chairman of the Committee, Juha Kauppinen, represents own shareholdings, Lars Moberg, represents own shareholdings, Kerstin Jakobsson, Observer, Chairman Diagonal Bio AB and Ylber Rexhepi no longer qualifies.
お知らせ • Nov 19Diagonal Bio AB (publ), Annual General Meeting, May 20, 2025Diagonal Bio AB (publ), Annual General Meeting, May 20, 2025.
お知らせ • Nov 13Diagonal Bio AB (publ) Announces Pilot Test with LAMPlify at Kolgjini StablesDiagonal Bio AB (publ) announced a partnership with Kolgjini Stables (Stall Kolgjini, to conduct a three-month pilot test. Kolgjini Stables is a Swedish stable known for its expertise in growing horses for both breeding and for top-tier national and international competition. This pilot test starts immediately and aims to evaluate the potential of the LAMPlify® platform to provide rapid and accurate virus detection in horses. KolgjiniStables, led by Lutfi Kolgjini, is a prominent player both in harness racing and horse breeding. The facility, located near Lund holds up to 180 horses. The large number of horses in proximity makes rapid virus detection especially critical to prevent the spread of infections within the stables. A rapid diagnostic method allows breeders to promptly isolate infected horses, proactively safeguarding their animals' health and minimising the risk of transmission. The pilot test at Kolgjini Stables are part of Diagonal Bio's ongoing strategy to commercialise the LAMPlify®®? solution aimed at horse breeders seeking solutions to prevent the spreading of viruses. The result of this pilot test will help ensure that LAMPlify® effectively meets the specific needs of the horse breeding and racing industry.
Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr1.24m (loss narrowed 53% from 3Q 2023).
お知らせ • Nov 01+ 3 more updatesDiagonal Bio AB (publ) to Report Q3, 2025 Results on Oct 31, 2025Diagonal Bio AB (publ) announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Oct 25Diagonal Bio AB (publ) Announces Pilot Test of LAMPlify at Norwegian University of Life SciencesDiagonal Bio AB (publ) announced the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify, at the Norwegian University of Life Sciences (NMBU) in Ås. The pilot, which will be conducted in collaboration with the Faculty of Veterinary Medicine and Biosciences, specifically the Department of Companion Animal Clinical Sciences, aims to evaluate the effectiveness and potential integration of LAMPlify within the university's equine hospital. The veterinary team at NMBU, led by Associate Professor Ingunn Risnes Hellings, will test LAMPlify in their animal hospital laboratory. As a leading teaching and commercial hospital, the equine department treats horses from across Norway, and this pilot will explore the feasibility of adopting LAMPlify as a vital tool for rapid, on-site diagnostics in their medicine department. The pilot test will provide crucial insights into whether LAMPlify can meet the hospital's needs for efficient, point- of-care diagnostics, potentially transforming the way they manage and treat equine patients.
お知らせ • Oct 12Diagonal Bio Announces Successful External Validation of LAMPlify for Viruses in PigusesDiagonal Bio AB (publ) announced successful results of a recent pilot study conducted by the Centre for Diagnostics at DTU Health Technology. The study evaluated the performance of the LAMPlify assay panel for tests specific to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) type 1 and type 2, and Swine Influenza Virus (SIV), by comparing it to the gold-standard PCR (qPCR) tests. The study showed excellent agreement between the LAMPlify®?assays and qPCR tests, yielding identical positive/negative classifications between the methods. The samples were selected by Centre for Diagnostics, DTU (Danmarks Tekniske Universitet), among the ones submitted for diagnostic examination at the Veterinary Institute. In total, four PRRSV1 positive, one PRRSV2 positive and eight SIV positive samples were included in this study.
お知らせ • Oct 09Diagonal Bio AB (publ) Announces Hunneberga Horse Stable to Conduct Pilot Test of LAMPlifyDiagonal Bio AB announces that Hunneberga Horse Stable (Hunneberga Hästgård) and Tomas Hammar, showjumping trainer and CEO at Hunneberga Horse Stable, has initiated a partnership with Diagonal Bio to conduct a pilot test. The agreement is set to three months and will involve a testing program of LAMPlify to detect respiratory viral infections in showjumping horses during upcoming competitions. The pilot will start immediately. Tomas Hammar, responsible for 20 competition horses and actively participating in both national and international events, sees great value in continuously ensuring the health of those horses through regular testing. At competitions, where horses from different stables gather, there is always a risk that infectious diseases such as respiratory viruses, influenza, and herpes viruses (for example EHV1 and EHV4) are spread. These viruses can spread quickly and affect both the well-being of the horses and their ability to compete. This pilot test is intended to provide faster and more accurate point-of-care diagnostics, thereby enhancing health outcomes for showjumping horses and ensuring more secure horse competitions. The pilot, which will run for three months, will involve using LAMPlify® on Hunneberga Horse Stable's horses at every event, both to protect their own horses and to demonstrate the technology to other trainers and horse owners. The study also aims to showcase how LAMPlify can become a new standard for quick and easy testing within the equestrian sports.
Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr3.44m (loss widened 23% from 2Q 2023).
Reported Earnings • Jun 04First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr255.0k (down 75% from 1Q 2023). Net loss: kr2.99m (loss narrowed 19% from 1Q 2023).
お知らせ • Jun 02+ 2 more updatesDiagonal Bio AB (publ) to Report Q2, 2024 Results on Aug 22, 2024Diagonal Bio AB (publ) announced that they will report Q2, 2024 results on Aug 22, 2024
お知らせ • May 24Diagonal Bio AB (publ) Appoints Fata Mrsic as Chief Financial Officer, Effective June 14, 2024Diagonal Bio AB (publ) has appointed Fata Mrsic as the new Chief Financial Officer (CFO). Fata will assume the position on June 14, 2024, and be part of the Management Team. Fata Mrsic has extensive financial and accounting experience. She has held Business Controller and Accounting positions at several companies in the past 15 years, some with global presence. Fata has a Diploma in Business Controlling from the University of Lund.
お知らせ • May 16Diagonal Bio AB (publ), Annual General Meeting, Jun 11, 2024Diagonal Bio AB (publ), Annual General Meeting, Jun 11, 2024, at 13:00 W. Europe Standard Time. Location: at medicon village, scheeletorget 1, lund Sweden
お知らせ • Apr 05Diagonal Bio AB (Publ) Announces Successful Pilot Study ResultsDiagonal Bio AB (publ) announced the extension of its partnership with Horsholm Veterinary Clinic following the successful completion of a three-month pilot study. The pilot study was focused on utilizing Diagonal Bio's platform technology, LAMPlify®, for the detection of viral infections in horses. The successful results were validated by an independent external laboratory in Germany, underscoring the efficacy and reliability of the LAMPlify® analysis system. The pilot study tested Diagonal Bio's LAMPlify® technology on a series of samples from horses suspected of carrying respiratory viruses. The tests confirmed the presence of virus infections in several of the horses tested. The pilot study not only demonstrated LAMPlify®'s capability to accurately identify viral infections but also proved that it is a valuable tool in the early detection of such diseases, thereby enabling timely intervention and treatment.
Reported Earnings • Mar 01Full year 2023 earnings released: kr0.34 loss per share (vs kr1.70 loss in FY 2022)Full year 2023 results: kr0.34 loss per share (improved from kr1.70 loss in FY 2022). Revenue: kr3.18m (down 14% from FY 2022). Net loss: kr11.7m (loss narrowed 28% from FY 2022).
お知らせ • Feb 29Diagonal Bio Appoints Karin Wehlin as New CEODiagonal Bio AB (publ) announced that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin is currently Diagonal Bio’s interim CEO. Karin Wehlin was elected to the Board of Directors of Diagonal Bio in the spring of 2023, and on November 23, 2023, she was appointed as interim CEO. Karin holds an Executive MBA degree from Lund University and has completed education at INSEAD in Strategy, Innovation, and Leadership. She has over 25 years of experience in senior positions within the Life Science sector, and has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB. Karin has also worked as Manager in Corporate Finance and is the founder of EQL Pharma AB, where she served as the Executive Chairman of the board for 10 years.
New Risk • Nov 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 12% over the past year. Shareholders have been substantially diluted in the past year (337% increase in shares outstanding). Revenue is less than US$1m (kr3.6m revenue, or US$327k). Market cap is less than US$10m (€1.31m market cap, or US$1.41m).
Reported Earnings • Nov 06Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr789.0k (down 39% from 3Q 2022). Net loss: kr2.66m (loss narrowed 29% from 3Q 2022).
Board Change • Aug 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 23Diagonal Bio AB (publ) announced that it expects to receive SEK 1.8 million in fundingDiagonal Bio AB announced a private placement to issue common shares for the gross proceeds of SEK 1,800,000 on August 22, 2023.
Board Change • Jul 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 26Full year 2022 earnings released: kr1.77 loss per share (vs kr1.70 loss in FY 2021)Full year 2022 results: kr1.77 loss per share (further deteriorated from kr1.70 loss in FY 2021). Revenue: kr3.73m (down 57% from FY 2021). Net loss: kr16.2m (loss widened 39% from FY 2021).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Kerstin Jakobsson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.